Niklas Klümper
@niklaskluemper.bsky.social
GU oncologist, Interested in precision oncology. ADC biomarker development. NECTIN4. Clinician Scientist. PI of translational research group at the University Hospital Bonn. Opinions are my own
Happy to share our manuscript titled 'Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy' published in JAMA Oncology!
@jama.com
jamanetwork.com/journals/jam...
@jama.com
jamanetwork.com/journals/jam...
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
jamanetwork.com
December 27, 2024 at 8:23 PM
Happy to share our manuscript titled 'Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy' published in JAMA Oncology!
@jama.com
jamanetwork.com/journals/jam...
@jama.com
jamanetwork.com/journals/jam...
Reposted by Niklas Klümper
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
jamanetwork.com
December 26, 2024 at 8:55 PM
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Reposted by Niklas Klümper
Great review! NECTIN4 is an exciting target. More to come !
#cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker
#cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker
Nectin-4 Positivity in GU Malignancies - Emanuele Crupi
oncodaily.com/insight/eman...
#BladderCancer #Cancer #GUMalignancies #Health #JCOPrecisionOncology #OncoDaily #Oncology #Medicine
oncodaily.com/insight/eman...
#BladderCancer #Cancer #GUMalignancies #Health #JCOPrecisionOncology #OncoDaily #Oncology #Medicine
Emanuele Crupi: Nectin-4 Positivity in GU Malignancies - OncoDaily
Emanuele Crupi: Nectin-4 Positivity in GU Malignancies / Andrea Necchi, bladder cancer, cancer, Daniele Raggi, Emanuele Crupi, GU malignancies, JCO Precision
oncodaily.com
December 11, 2024 at 9:10 AM
Great review! NECTIN4 is an exciting target. More to come !
#cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker
#cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker
Reposted by Niklas Klümper
Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24
December 5, 2024 at 5:47 PM
Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24
Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social
December 11, 2024 at 9:12 AM
Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social